CompletedPhase 4

N-Acetyl Cysteine Effect on Liver Function After Mitral Valve Replacement

Egypt54 participantsStarted 2024-06-30

Plain-language summary

This study aimed at the impact of the N-acetyl cysteine on the improvement of liver function subsequently on-pum mitral valve replacement. Following a clinical trial design, 54 candidates of on-pump MVR, aged 18 to 70 years, with normal liver and renal function were selected. The candidates were randomly divided into intervention: IV150 mg/ kg N-acetyl cysteine over 15 min, and control groups (normal saline as placebo) (n = 27 in each group).

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age from 18 to 70 years * Both sexes * Patients undergoing on-pump elective MVR with cold cardioplegia. Exclusion Criteria: * Patient refusal. * Allergy to any of the study medications. * Emergency procedures. * systolic dysfunction, left ventricular ejection fraction \<40%. * Pre-existing hepatic dysfunction, which is defined as an increase in liver enzymes AST and ALT \>10 times the baseline. * chronic use of drugs affecting liver functions, e.g., NSAIDs, steroids, and anticonvulsants.

What they're measuring

Malondialdahyde (MDA)

Timeframe: Postoperative day one

Trial details

NCT IDNCT06486805

SponsorKasr El Aini Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-11-30

View on ClinicalTrials.gov More Oxidative Stress trials